Leaflet CO-ATORIS 80mg / 10mg film-coated tablets

Indicated for: dyslipidemia

Route of administration: oral

Substance: atorvastatin + ezetimibe (statin lipid-lowering agent + lipid-lowering agent)

ATC: C10BA05 (Cardiovascular system | Lipid modifying agents, combinations | Combinations of various lipid modifying agents)

Precautions:
Avoid grapefruit
Avoid grapefruit

Avoid grapefruit and grapefruit juice.

Hepatotoxicity
Hepatotoxicity

This medicine may affect the liver.

Major drug interactions
Major drug interactions

This medicine may have important interactions with other medicines.

Myopathy / rhabdomyolysis
Myopathy / rhabdomyolysis

Seek medical advice if unexplained muscle pain occurs.

Requires periodic laboratory tests
Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Pregnancy warning
Pregnancy warning

Use during pregnancy only on medical advice.

The combination of atorvastatin and ezetimibe is used for the treatment of dyslipidemia, particularly in patients with primary or familial hypercholesterolemia. Atorvastatin is an HMG-CoA reductase inhibitor that reduces cholesterol synthesis in the liver, while ezetimibe inhibits cholesterol absorption in the intestine. Through their complementary actions, these medications significantly lower LDL cholesterol levels.

This combination is administered orally, usually once daily, with the dosage adjusted based on lipid levels and the patient's response to treatment. It is particularly indicated for patients who do not achieve lipid targets with statins alone or who require additional LDL cholesterol reduction.

Common side effects include headaches, fatigue, muscle pain, diarrhea, and nausea. In rare cases, severe adverse reactions such as rhabdomyolysis, hepatotoxicity, or pancreatitis may occur.

Patients taking this combination should undergo regular monitoring for liver function and lipid levels. The atorvastatin and ezetimibe combination provides an effective option for reducing cardiovascular risk, helping to prevent major cardiovascular events.

General data about CO-ATORIS 80mg / 10mg

  • Substance: atorvastatin + ezetimibe
  • Date of latest medicines list: 01-03-2025
  • Product code: W70920001
  • Concentration: 80mg / 10mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 10
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: KRKA, D.D., NOVO MESTO - SLOVENIA
  • Holder: KRKA, D.D., NOVO MESTO - SLOVENIA
  • Number: 15826/2025/01
  • Shelf life: 2 years

Concentrations available for atorvastatin + ezetimibe

  • 20mg/10mg
  • 40mg/10mg
  • 80mg/10mg